Literature DB >> 9085042

Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery.

S Wei1, Y Kasuya, M Yanagisawa, S Kimura, T Masaki, K Goto.   

Abstract

Hydralazine relaxed porcine coronary artery strips in a concentration-dependent manner by distinct endothelium-dependent and endothelium-independent actions. With lower doses (< or = 10(-6) M), the hydralazine-induced relaxation appears to be completely endothelium-dependent and we designed the present study to elucidate the mechanisms of this endothelium-dependent relaxation. Hydralazine (10(-6) M)-induced endothelium-dependent relaxation was not affected by the presence of 10(-5) M indomethacin, 10(-3) M L-NG-nitro-arginine (L-NOARG) or 10(-5) M haemoglobin, and was accompanied by accumulation of cGMP but not of cAMP in artery strips. There was a close time-dependent parallel relationship between endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine (10(-6) M). The endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine showed much slower kinetics than those induced by ionomycin (10(-7) M). Pretreatment of the strips with actinomycin D (10 micrograms/ml) significantly inhibited not the endothelium-dependent relaxation and accumulation of cGMP induced by ionomycin (10(-7) M) but those induced by hydralazine (10(-6) M). These results suggest that hydralazine induces endothelium-dependent vasorelaxation via the slow accumulation of cGMP in the strips. This does not occur through the release of nitric oxide or prostaglandin I2 but through immediate transcription and probably expression of a molecule in the endothelium.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9085042     DOI: 10.1016/s0014-2999(96)00972-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo.

Authors:  K Andersson; N Gaudiot; C Ribiere; M Elizalde; Y Giudicelli; P Arner
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester.

Authors:  Ibrahim F Benter; Mariam H M Yousif; Fatemah M Al-Saleh; Raj Raghupathy; Mark C Chappell; Debra I Diz
Journal:  J Cardiovasc Pharmacol       Date:  2011-05       Impact factor: 3.105

3.  Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery.

Authors:  D C Ellershaw; A M Gurney
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

4.  Control of hypertension in the critically ill: a pathophysiological approach.

Authors:  Diamantino Ribeiro Salgado; Eliezer Silva; Jean-Louis Vincent
Journal:  Ann Intensive Care       Date:  2013-06-27       Impact factor: 6.925

5.  Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission.

Authors:  Siavash Beikoghli Kalkhoran; Janos Kriston-Vizi; Sauri Hernandez-Resendiz; Gustavo E Crespo-Avilan; Ayeshah A Rosdah; Jarmon G Lees; Joana Rodrigues Simoes Da Costa; Naomi X Y Ling; Jessica K Holien; Parisa Samangouei; Kroekkiat Chinda; En Ping Yap; Jaime A Riquelme; Robin Ketteler; Derek M Yellon; Shiang Y Lim; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.